Major technical sections complete for Zenrelia, with FDA final approval on track for late in third quarter of 2024; updates on differentiation and safety Final FDA approval for Credelio Quattro now expected in the fourth quarter of 2024 First Zenrelia approval received in Brazil 2024 Innovation sales guidance increased GREENFIELD, Ind., June 27, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced updates to the expected U.S. Food and Drug Administration (FDA) approval timelin ...

A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. Most Powerful Force Impacting Stock Prices Elanco Animal Health Incorporated (ELAN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one ...

GREENFIELD, Ind., June 6, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Goldman Sachs 45th Annual Global Healthcare Conference, June 11-12, 2024. Jeff Simmons, President and CEO, will participate in a fireside chat on Tuesday, June 11 at 2:40 p.m. ET. A live audio webcast will be available in the "Events and Presentations" section of Elanco's investor website. A replay will be available for approximately 30 days. ABOUT ELANCO Elanco Animal Health Incorporated (NYSE: ELA ...

Food and Drug Administration confirms Bovaer meets safety and efficacy requirements Elanco expects product launch and added carbon credit value to producers beginning in the third quarter Elanco announces agreement with dsm-firmenich to expand distribution of Bovaer across North America, adding both the Canada and Mexico markets GREENFIELD, Ind., May 28, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Food and Drug Administration (FDA) has completed its comprehen ...

Elanco Animal Health Incorporated (NYSE:ELAN) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Jeff Simmons - President, Chief Executive Officer Todd Young - Executive Vice President, Chief Financial Officer Katy Grissom - Head of Investor Relations Conference Call Participants Jon Block - Stifel Erin Wright - Morgan Stanley Michael Ryskin - Bank of America Mike DiFiore - Evercore ISI Ekaterina Knyazkova - JP Morgan Brandon Vazquez - William Blair Nathan Rich - Goldman Sachs Dav ...

Elanco Animal Health Incorporated (ELAN) reported $1.21 billion in revenue for the quarter ended March 2024, representing a year-over-year decline of 4.1%. EPS of $0.34 for the same period compares to $0.45 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.17 billion, representing a surprise of +2.69%. The company delivered an EPS surprise of +30.77%, with the consensus EPS estimate being $0.26.While investors closely watch year-over-year changes in headline numbers -- revenue a ...

[Forward-Looking Statements and Risk Factor Summary](index=4&type=section&id=FORWARD-LOOKING%20STATEMENTS%20AND%20RISK%20FACTOR%20SUMMARY) [Forward-Looking Statements](index=4&type=section&id=Forward-Looking%20Statements) Forward-looking statements are based on current expectations and assumptions, subject to inherent uncertainties and risks that may cause actual results to differ materially - Forward-looking statements are based on current expectations and assumptions, subject to inherent uncertainties, risks, and changes in circumstances that could cause actual results to differ materially[10](index=10&type=chunk) [Risk Factor Summary](index=4&type=section&id=Risk%20Factor%20Summary) Key risk factors include competitive industry dynamics, R&D success, regulatory changes, operational challenges, financial leverage, and macroeconomic conditions - Key risk factors include operating in a highly competitive industry, success of R&D and licensing efforts, impact of disruptive innovations, competition from generic products, changes in regulatory restrictions, and risks related to infectious disease outbreaks[11](index=11&type=chunk) - Financial risks include substantial indebtedness, changes in interest rates, goodwill write-downs, and foreign currency exchange rate fluctuations[11](index=11&type=chunk) - Operational and strategic risks encompass the ability to complete acquisitions/divestitures, implement business strategies, manage manufacturing problems, address IT system breaches, and navigate legal, regulatory, and environmental challenges[11](index=11&type=chunk)[14](index=14&type=chunk) [PART I. Financial Information](index=4&type=section&id=PART%20I.%20Financial%20Information) [Item 1. Financial Statements](index=4&type=section&id=Item%201.%20FINANCIAL%20STATEMENTS) Elanco's unaudited Q1 2024 condensed consolidated financial statements are presented, covering operations, comprehensive income, balance sheets, equity, and cash flows, with detailed notes [Condensed Consolidated Statements of Operations (Unaudited)](index=6&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20OPERATIONS%20(UNAUDITED)) | Metric (in millions) | 3 Months Ended March 31, 2024 | 3 Months Ended March 31, 2023 | % Change | | :------------------------- | :----------------------------- | :----------------------------- | :------- | | Revenue | $1,205 | $1,257 | (4)% | | Net income | $32 | $103 | (69)% | | Basic EPS | $0.06 | $0.21 | (71.4)% | | Diluted EPS | $0.06 | $0.21 | (71.4)% | | Cost of sales | $515 | $494 | 4% | | R&D | $87 | $81 | 7% | | Marketing, selling & admin | $337 | $327 | 3% | | Income before income taxes | $12 | $108 | (89)% | | Income tax (benefit) expense | $(20) | $5 | NM | [Condensed Consolidated Statements of Comprehensive (Loss) Income (Unaudited)](index=7&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20COMPREHENSIVE%20(LOSS)%20INCOME%20(UNAUDITED)) | Metric (in millions) | 3 Months Ended March 31, 2024 | 3 Months Ended March 31, 2023 | | :---------------------------------------- | :----------------------------- | :----------------------------- | | Net income | $32 | $103 | | Other comprehensive (loss) income, net of taxes | $(199) | $82 | | Comprehensive (loss) income | $(167) | $185 | [Condensed Consolidated Balance Sheets](index=8&type=section&id=CONDENSED%20CONSOLIDATED%20BALANCE%20SHEETS) | Metric (in millions) | March 31, 2024 | December 31, 2023 | Change (in millions) | | :------------------------ | :------------- | :---------------- | :------------------- | | Total assets | $14,019 | $14,362 | $(343) | | Total liabilities | $7,963 | $8,139 | $(176) | | Total equity | $6,056 | $6,223 | $(167) | | Cash and cash equivalents | $345 | $352 | $(7) | | Accounts receivable, net | $988 | $842 | $146 | | Inventories | $1,638 | $1,735 | $(97) | | Assets held for sale | $651 | $0 | $651 | | Goodwill | $4,478 | $5,094 | $(616) | | Long-term debt | $5,727 | $5,736 | $(9) | [Condensed Consolidated Statements of Equity (Unaudited)](index=9&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20EQUITY%20(UNAUDITED)) - Total equity decreased from **$6,223 million** at December 31, 2023, to **$6,056 million** at March 31, 2024[22](index=22&type=chunk)[24](index=24&type=chunk) - Net income contributed **$32 million** to equity, while other comprehensive loss, net of tax, reduced equity by **$199 million**[24](index=24&type=chunk) - Stock-based compensation activity resulted in **1.2 million** additional shares outstanding[24](index=24&type=chunk) [Condensed Consolidated Statements of Cash Flows (Unaudited)](index=10&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20CASH%20FLOWS%20(UNAUDITED)) | Cash Flow Activity (in millions) | 3 Months Ended March 31, 2024 | 3 Months Ended March 31, 2023 | Change (in millions) | | :---------------------------------------- | :----------------------------- | :----------------------------- | :------------------- | | Operating activities | $2 | $(145) | $147 | | Investing activities | $37 | $(55) | $92 | | Financing activities | $(27) | $174 | $(201) | | Net decrease in cash and cash equivalents | $(7) | $(27) | $20 | [Notes to Condensed Consolidated Financial Statements (Unaudited)](index=11&type=section&id=NOTES%20TO%20CONDENSED%20CONSOLIDATED%20FINANCIAL%20STATEMENTS%20(UNAUDITED)) [Note 1. Basis of Presentation and Summary of Significant Accounting Policies](index=11&type=section&id=Note%201.%20Basis%20of%20Presentation%20and%20Summary%20of%20Significant%20Accounting%20Policies) Unaudited financial statements are prepared per SEC interim reporting, with interim results not indicative of full-year performance, and estimates subject to variation - Financial statements are unaudited and prepared per SEC interim reporting rules, condensing GAAP disclosures[30](index=30&type=chunk) - Interim results are not indicative of full-year performance[30](index=30&type=chunk) - Estimates and assumptions are made, and actual results may differ[31](index=31&type=chunk) [Note 2. New Financial Accounting Pronouncements](index=11&type=section&id=Note%202.%20New%20Financial%20Accounting%20Pronouncements) The company is assessing ASU 2023-07 (Segment Reporting) and ASU 2023-09 (Income Taxes), effective for fiscal years after December 31, 2023, and 2024 - ASU 2023-07 (Segment Reporting) is effective for fiscal years beginning after **December 31, 2023**, aiming to improve disclosures about significant segment expenses[33](index=33&type=chunk) - ASU 2023-09 (Income Taxes) is effective for fiscal years beginning after **December 31, 2024**, aiming to enhance transparency of income tax disclosures[33](index=33&type=chunk) - The company is currently assessing the impact of both ASUs on its consolidated financial statements and footnote disclosures[33](index=33&type=chunk) [Note 3. Revenue](index=11&type=section&id=Note%203.%20Revenue) Revenue from product sales is recognized upon shipment, with rebates reducing revenue, and is disaggregated by product category and geographic area - Revenue from product sales is recognized when the customer obtains control of goods, typically upon shipment[34](index=34&type=chunk) - Sales rebates and discounts are recorded as a reduction to revenue based on specific agreements and estimates[36](index=36&type=chunk) | Category | 2024 (in millions) | 2023 (in millions) | | :--------------------- | :----------------- | :----------------- | | Pet Health | $639 | $675 | | Farm Animal | $556 | $573 | | Contract Manufacturing | $10 | $9 | | **Total Revenue** | **$1,205** | **$1,257** | | Region | 2024 (in millions) | 2023 (in millions) | | :------------ | :----------------- | :----------------- | | United States | $531 | $543 | | International | $674 | $714 | | **Total Revenue** | **$1,205** | **$1,257** | [Note 4. Acquisitions, Divestitures and Other Arrangements](index=12&type=section&id=Note%204.%20Acquisitions

+$10M of cash from inventory, while building approx. $15M of inventory for launches Note: Numbers may not add due to rounding. 1Net debt is a non-GAAP measure calculated as gross debt less cash and cash equivalents on our balance sheet. Gross debt is the sum of the current portion of long-term debt and long-term debt and excludes unamortized debt issuance costs. 2Net leverage ratio is calculated as net debt divided by trailing 12 month adjusted EBITDA. This calculation does not include Term Loan B covenant- ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or kathryn.grissom@elancoah.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Elanco Animal Health Reports First Quarter 2024 Results GREENFIELD, Ind (May 8, 2024) - Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the first quarter of 2024, provided guidance for the second quarter of 2024, and updated guidance for the full year 2024. "Elanco's strong busi ...

Wall Street analysts forecast that Elanco Animal Health Incorporated (ELAN) will report quarterly earnings of $0.26 per share in its upcoming release, pointing to a year-over-year decline of 42.2%. It is anticipated that revenues will amount to $1.17 billion, exhibiting a decline of 6.6% compared to the year-ago quarter.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraise ...